Careers

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families battling challenging diseases. Our lead therapeutic asset, Trappsol® Cyclo™, is a proprietary formulation of hydroxypropyl beta cyclodextrin and in multiple clinical studies has shown encouraging results to effectively manage the transportation of cholesterol. Taking the place of the defective NPC1 protein, Trappsol® Cyclo™, with its cyclic structure, captures cholesterol within the cell and transports it out of the cell. Trappsol® Cyclo™ is currently being tested in clinical trials for the treatment of Niemann-Pick Type C1 (NPC), a rare, fatal and progressive genetic disorder and Alzheimer’s disease, an irreversible, progressive neurological disorder.